Summary
NG9 Chart
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeoGenomics Inc. (NG9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has NeoGenomics Inc. ever had a stock split?
NeoGenomics Inc. Profile
| Professional Services Industry | Industrials Sector | Anthony P. Zook CEO | XFRA Exchange | US64049M2098 ISIN |
| US Country | 2,200 Employees | - Last Dividend | 16 Apr 2003 Last Split | 2 Nov 1999 IPO Date |
Overview
NeoGenomics, Inc. is a specialized laboratory network that focuses on cancer diagnostics and operates within the United States and the United Kingdom. Since its inception in 2001 and based in Fort Myers, Florida, the company has grown to provide a comprehensive range of testing services through its Clinical Services and Advanced Diagnostics segments. These services cater to an array of clients including hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. With a strong emphasis on supporting the diagnosis, treatment, and monitoring of cancer, NeoGenomics stands out for its dedication to advancing oncology diagnostics.
Products and Services
NeoGenomics, Inc. offers a diverse portfolio of diagnostic services, further detailed below:
- Cytogenetics Testing Services: This service examines both normal and abnormal chromosomes to understand their link to diseases. It's pivotal for revealing genetic conditions related to chromosome abnormalities.
- Fluorescence In-Situ Hybridization (FISH) Testing Services: Specializing in detecting and pinpointing the presence or absence of specific DNA sequences and genes on chromosomes, FISH plays a crucial role in genetic disease diagnosis and management.
- Flow Cytometry Testing Services: By measuring the physical and chemical characteristics of cell populations, this service provides invaluable data for research and clinical purposes, particularly in hematology.
- Immunohistochemistry and Digital Imaging Testing Services: These services focus on localizing cellular proteins in tissue sections. Moreover, they enable clients to visualize scanned slides and perform quantitative analyses, enhancing diagnostic precision.
- Molecular Testing Services: This service focuses on the analysis of DNA and/or RNA, along with the structure and function of genes at the molecular level, which is essential for the diagnosis of genetic disorders, infectious diseases, and cancers.
- Morphologic Analysis: Conducting an examination of cells under a microscope allows pathologists to diagnose various conditions accurately based on the appearance and structure of cells.
- Pharmaceutical Services: Supporting pharmaceutical clients’ oncology programs, these services range from the discovery phase through to commercialization, thus facilitating the development of new cancer treatments.
Contact Information
